2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal Of Cancer 2018, 101: 201-209. PMID: 30077125, DOI: 10.1016/j.ejca.2018.06.031.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsBaseline PD-L1 expressionObjective response ratePD-L1 expressionPD-L1Immune cellsGrade treatment-related adverse eventsSurvival rateCell lung cancer cohortLong-term clinical benefitTumor-infiltrating immune cellsTumor cellsPhase IPrevious systemic therapySingle-agent atezolizumabCell lung cancerExploratory subgroup analysisLung cancer cohortAtezolizumab monotherapyAdverse eventsDurable responsesMedian durationSystemic therapyAnticancer immunityPD-1ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Wu YL, Herbst R, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer 2018, 19: e533-e536. PMID: 29789220, DOI: 10.1016/j.cllc.2018.04.004.Peer-Reviewed Original ResearchConceptsCell lung cancerDisease recurrenceLung cancerMutation statusSurvival rateEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsComplete surgical tumor resectionDisease-free survival ratesT790M mutation statusReceptor tyrosine kinase inhibitorsMaximum treatment durationStage IB-IIIAPlacebo-controlled studyDisease-free survivalEarly-stage NSCLCComplete surgical resectionOverall survival rateHealth-related qualityHealth resource useSurgical tumor resectionEGFR mutation statusTyrosine kinase inhibitorsCentral confirmationVersus PlaceboClinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.Peer-Reviewed Original ResearchConceptsPD-1 axis inhibitorsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerInhibitor therapyLocal therapyLymph nodesLung cancerSurvival rateSolid Tumors v1.1Response Evaluation CriteriaSite of diseaseProgression of diseaseProgressive diseaseClinical patternLN metastasisSuch patientsClinical featuresMedian timeRadiographic featuresTumor regressionProlonged benefitPatientsTherapyResponse criteriaThe biology and management of non-small cell lung cancer
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018, 553: 446-454. PMID: 29364287, DOI: 10.1038/nature25183.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerSmall molecule tyrosine kinase inhibitorsMolecule tyrosine kinase inhibitorsBroader patient populationTyrosine kinase inhibitorsUnprecedented survival benefitsMetastatic diseaseMultimodal careSurvival benefitClinical benefitCombination therapyOverall curePatient populationSurvival rateTumor progressionEarly detectionKinase inhibitorsNew drugsDisease biologyCancerImmunotherapyPatientsTherapy
2017
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.
Hellmann M, Ma J, Garon E, Hui R, Gandhi L, Soria J, Anderson K, Lubiniecki G, Piperdi B, Herbst R. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Journal Of Clinical Oncology 2017, 35: 77-77. DOI: 10.1200/jco.2017.35.7_suppl.77.Peer-Reviewed Original ResearchNon-small cell lung cancerLong-term survival ratesLong-term survivalAdvanced non-small cell lung cancerKEYNOTE-001KEYNOTE-010PD-L1Survival rateOverall survivalLong-term benefitsLong-term survival modelsNon-small cell lung cancer patientsCell lung cancer patientsPercentage of patientsSurvival modelsCell lung cancerLung cancer patientsTreat populationDocetaxel armPembrolizumab monotherapyParametric survival modelsCancer patientsLung cancerPatientsSubsequent independent validation
2007
P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC
Cleverly A, Bepler G, Oh Y, Burris H, Herbst R, Lahn M. P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC. European Journal Of Cancer Supplements 2007, 5: 30. DOI: 10.1016/s1359-6349(08)70079-x.Peer-Reviewed Original Research
2006
Asian Ethnicity as a Predictor of Response in Patients with Non–Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program
Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian Ethnicity as a Predictor of Response in Patients with Non–Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program. Clinical Lung Cancer 2006, 7: 326-331. PMID: 16640804, DOI: 10.3816/clc.2006.n.014.Peer-Reviewed Original ResearchConceptsExpanded Access ProgramCell lung cancerLung cancerAsian ethnicityD. Anderson Cancer CenterPartial response rateStable disease rateAdvanced-stage NSCLCPredictors of responseAccess programAnderson Cancer CenterEast Asian ethnicityChart reviewMedian survivalPartial responseIndependent predictorsMedian timeSmoking statusRetrospective studyCancer CenterPatientsResponse rateSurvival rateMultivariate analysisGefitinib
2005
Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2005, 24: 190-205. PMID: 16326753, DOI: 10.1200/jco.2005.04.8678.Peer-Reviewed Original ResearchConceptsClinical OncologyCancer typesClinical researchCancer treatmentScreening—A ReportRisk of recurrenceCancer therapyAmerican SocietyQuality of lifeSignificant clinical researchStudy of drugsCancer survivorsCommon cancerClinical trialsEffective therapyTargeted cancer therapyLong-term effectsNew chemotherapySurvival ratePatient careCancerTherapyEnormous tollDiseaseCancer researchLimited-Stage Small-Cell Lung Cancer (Stages I-III): Observations from the National Cancer Data Base
Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-Stage Small-Cell Lung Cancer (Stages I-III): Observations from the National Cancer Data Base. Clinical Lung Cancer 2005, 6: 355-360. PMID: 15943896, DOI: 10.3816/clc.2005.n.015.Peer-Reviewed Original ResearchConceptsLimited stage small cell lung cancerSmall cell lung cancerLS-SCLCChemoradiation therapyStandard treatmentLung cancerRadiation therapySole treatmentSurvival rateConcurrent thoracic radiation therapyNational Cancer Data BaseMultiple-agent chemotherapyTreatment pattern changesPercent of patientsProportion of patientsThoracic radiation therapyUse of chemotherapyUse of chemoradiationAge of patientsGroup of patientsConfidence intervalsYears of agePercentage of womenCombined chemotherapyPatient cohort
2003
Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens
Blumenschein GR, Herbst RS. Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens. Clinical Lung Cancer 2003, 4: 217-223. PMID: 14624709, DOI: 10.3816/clc.2003.n.001.Peer-Reviewed Original ResearchLung cancerTargeted therapyCell lung cancerReceptor-targeted therapyLung cancer casesHigh mortality rateSpecific biologic pathwaysAdvanced NSCLCChemotherapy regimensCell cycle inhibitionMost patientsCommon malignancyPoor prognosisCancer casesTherapeutic improvementRadiation therapyEncouraging activityNew agentsMortality rateAngiogenesis inhibitionSingle agentClinical testingSurvival rateTherapyTargeted therapeutics
2002
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer 2002, 95: 340-353. PMID: 12124835, DOI: 10.1002/cncr.10629.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntimetabolites, AntineoplasticAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBiological TherapyCarcinoma, Non-Small-Cell LungCombined Modality TherapyDeoxycytidineDisease ProgressionFemaleGemcitabineHumansLung NeoplasmsMaleMiddle AgedSurvival RateVinblastineVinorelbineConceptsNonsmall cell lung carcinomaYear survival rateAdvanced nonsmall cell lung carcinomaThird-line therapyPhase II trialMedian survival timeCell lung carcinomaGrade 3Survival rateSignificant myelosuppressionStable diseaseII trialLung carcinomaSurvival timeStage IV nonsmall cell lung carcinomaDay 1Day 15Formal phase II trialCurrent phase II trialDose of vinorelbineGemcitabine/vinorelbineGrade 3 granulocytopeniaMedian performance statusMinimal grade 3Prior chemotherapy regimensAngiogenesis inhibitors in lung cancer
Kim ES, Herbst RS. Angiogenesis inhibitors in lung cancer. Current Oncology Reports 2002, 4: 325-333. PMID: 12044242, DOI: 10.1007/s11912-002-0008-0.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsCarcinoma, Non-Small-Cell LungCollagenCyclohexanesEndostatinsHumansLung NeoplasmsO-(Chloroacetylcarbamoyl)fumagillolPeptide FragmentsPlasminogenReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorSesquiterpenesSurvival RateThalidomideConceptsLung cancerAngiogenesis inhibitorsSurvival rateMajor public health problemVascular endothelial growth factor receptorOngoing randomized studiesCell lung cancerEndothelial growth factor receptorTraditional cytotoxic therapiesCancer-related deathImproved survival ratesPublic health problemSevere side effectsInhibitors of angiogenesisEndogenous angiogenesis inhibitorGrowth factor receptorMetastatic diseaseRandomized studyChemotherapy dosesClinical benefitCytotoxic therapyCyclooxygenase inhibitorRadiation therapySide effectsHealth problemsNovel therapeutics for head and neck cancer
Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Current Opinion In Oncology 2002, 14: 334-342. PMID: 11981281, DOI: 10.1097/00001622-200205000-00014.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaNeck cancerSurvival rateCell carcinomaLeading causeEpidermal growth factor receptor blockersAnti-epidermal growth factor receptor monoclonal antibodyNeck squamous cell carcinoma (HNSCC) patientsSquamous cell carcinoma patientsEpidermal growth factor receptor monoclonal antibodiesLong-term survival ratesGrowth factor receptor blockersNovel biologic agentsCell carcinoma patientsMedian survival rateReceptor monoclonal antibodyChemotherapy of headSixth leading causeCancer-related deathFifth leading causeTyrosine kinase inhibitorsFarnesyl transferase inhibitorsProcess of tumorigenesisReceptor blockers
2001
Emerging therapies in non-small-cell lung cancer
Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Annals Of Oncology 2001, 12: 739-744. PMID: 11484947, DOI: 10.1023/a:1011197500223.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCancer-related deathFive-year survival rateRole of chemotherapyMultiple randomized trialsAdvanced diseaseStage IADevastating causeMetastatic diseaseModality therapyOnly patientsRandomized trialsStage IVSurvival rateNew casesCancerChemotherapyTherapyDiseaseDeathPatientsYear 2000Trials
1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Herbst RS, Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. Seminars In Oncology 1999, 26: 67-70; discussion 71-2. PMID: 10585011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerVinorelbine/gemcitabineCell lung cancerMedian survivalSurvival rateStable diseasePartial responseLung cancerDisease progressionDay 1Treatment of NSCLCStandard platinum-based regimensGemcitabine/vinorelbineChemotherapy-naive patientsPerformance status 0Treatment-naive patientsPhase II studyPlatinum-based regimensCombination of vinorelbineMedian survival timeOverall response rateNonplatinum agentsStatus 0Vinorelbine combination